BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 20421271)

  • 21. [Prognostic value of 1q21 amplification in multiple myeloma].
    Abramova TV; Obukhova TN; Mendeleeva LP; Pokrovskaya OS; Gribanova EO; Ryzhko VV; Grebenyuk LA; Nareyko MV; Solovyev MV; Votyakova OM; Kulikov SM; Rusinov MA; Savchenko VG
    Ter Arkh; 2017; 89(7):32-38. PubMed ID: 28766538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance.
    Shi L; Wang S; Zangari M; Xu H; Cao TM; Xu C; Wu Y; Xiao F; Liu Y; Yang Y; Salama M; Li G; Tricot G; Zhan F
    Oncotarget; 2010 May; 1(1):22-33. PubMed ID: 20930946
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Globular C1q Receptor (gC1qR/p32/HABP1) Suppresses the Tumor-Inhibiting Role of C1q and Promotes Tumor Proliferation in 1q21-Amplified Multiple Myeloma.
    Xu J; Sun Y; Jiang J; Xu Z; Li J; Xu T; Liu P
    Front Immunol; 2020; 11():1292. PubMed ID: 32760394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma.
    Chang H; Trieu Y; Qi X; Xu W; Stewart KA; Reece D
    Leuk Res; 2007 Jun; 31(6):779-82. PubMed ID: 16996589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The combination of C-Myc rearrangement and 1q21 gain is associated with poor prognosis in multiple myeloma.
    Jin Y; Yu X; Du J; Li H; Tang W; Jia C; Zan Y; Chen M; Zhang Y; Yu M; Rong W; Zhou D; Zhuang J
    Ann Hematol; 2021 May; 100(5):1251-1260. PubMed ID: 33686491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gain/Amplification of Chromosome Arm 1q21 in Multiple Myeloma.
    Hanamura I
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33445467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overexpression of CDC28 protein kinase regulatory subunit 1B confers an independent prognostic factor in nasopharyngeal carcinoma.
    Lee SW; Lin CY; Tian YF; Sun DP; Lin LC; Chen LT; Hsing CH; Huang CT; Hsu HP; Huang HY; Wu LC; Li CF; Shiue YL
    APMIS; 2014 Mar; 122(3):206-14. PubMed ID: 23879533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The independent adverse prognostic significance of 1q21 gain/amplification in newly diagnosed multiple myeloma patients.
    You H; Jin S; Wu C; Wang Q; Yan S; Yao W; Shi X; Shang J; Yan L; Yao Y; Wang J; Wang P; Pan J; Wu D; Fu C
    Front Oncol; 2022; 12():938392. PubMed ID: 36276097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21(Waf1/Cip1) and p27(Kip1) in urothelial carcinoma: correlation with other cell-cycle-related proteins (Rb, p53, Ki-67 and PCNA) and clinicopathological features.
    Ioachim E; Michael M; Stavropoulos NE; Kitsiou E; Hastazeris K; Salmas M; Stefanaki S; Agnantis NJ
    Urol Int; 2004; 73(1):65-73. PubMed ID: 15263796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gene expression profiling defines a high-risk entity of multiple myeloma.
    Zhan FH; Barlogie B; John D S
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Apr; 32(2):191-203. PubMed ID: 17478923
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alterations in the expression of the cell cycle regulatory protein cyclin kinase subunit 1 in colorectal carcinoma.
    Shapira M; Ben-Izhak O; Bishara B; Futerman B; Minkov I; Krausz MM; Pagano M; Hershko DD
    Cancer; 2004 Apr; 100(8):1615-21. PubMed ID: 15073847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
    Chang H; Qi X; Jiang A; Xu W; Young T; Reece D
    Bone Marrow Transplant; 2010 Jan; 45(1):117-21. PubMed ID: 19448682
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implication of malignancy and prognosis of p27(kip1), Cyclin E, and Cdk2 expression in epithelial ovarian tumors.
    Sui L; Dong Y; Ohno M; Sugimoto K; Tai Y; Hando T; Tokuda M
    Gynecol Oncol; 2001 Oct; 83(1):56-63. PubMed ID: 11585414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 3-O-(Z)-coumaroyloleanolic acid overcomes Cks1b-induced chemoresistance in lung cancer by inhibiting Hsp90 and MEK pathways.
    Wang H; Sun M; Guo J; Ma L; Jiang H; Gu L; Wen H; Liao S; Chen J; Zeng B; Li Y; Li Y; Yu X; Feng Y; Zhou Y
    Biochem Pharmacol; 2017 Jul; 135():35-49. PubMed ID: 28288818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous P53 deletion and poor survival for multiple myeloma.
    Chang H; Yeung J; Qi C; Xu W
    Br J Haematol; 2007 Aug; 138(3):324-9. PubMed ID: 17555471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cell cycle regulators in multiple myeloma: prognostic implications of p53 nuclear accumulation.
    Pruneri G; Carboni N; Baldini L; Intini D; Colombi M; Bertolini F; Valentini S; Maisonneuve P; Viale G; Neri A
    Hum Pathol; 2003 Jan; 34(1):41-7. PubMed ID: 12605365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China.
    Gao W; Jian Y; Du J; Li X; Zhou H; Zhang Z; Yang G; Wang G; Tian Y; Li Y; Wu Y; Fu W; Li J; Chen W
    Cancer Med; 2020 Nov; 9(21):7819-7829. PubMed ID: 32881351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis.
    Varma A; Sui D; Milton DR; Tang G; Saini N; Hasan O; Mukherjee A; Joseph JJ; Bashir Q; Rondon G; Srour S; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Mehta R; Khouri IF; Ahmed H; Iyer S; Weber DM; Thomas SK; Manasanch E; Lee HC; Patel K; Ciurea SO; Shpall EJ; Orlowski RZ; Champlin RE; Qazilbash MH
    Biol Blood Marrow Transplant; 2020 Apr; 26(4):665-671. PubMed ID: 31881283
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer.
    Masciullo V; Sgambato A; Pacilio C; Pucci B; Ferrandina G; Palazzo J; Carbone A; Cittadini A; Mancuso S; Scambia G; Giordano A
    Cancer Res; 1999 Aug; 59(15):3790-4. PubMed ID: 10446997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Altered expression of p27(Kip1) -interacting cell-cycle regulators in the adult testicular germ cell tumors: potential role in tumor development and histological progression.
    Miyai K; Yamamoto S; Iwaya K; Asano T; Tamai S; Tsuda H; Matsubara O
    APMIS; 2012 Nov; 120(11):890-900. PubMed ID: 23009113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.